CA2318808A1 - Compositions and methods for biocompatible implants - Google Patents
Compositions and methods for biocompatible implants Download PDFInfo
- Publication number
- CA2318808A1 CA2318808A1 CA002318808A CA2318808A CA2318808A1 CA 2318808 A1 CA2318808 A1 CA 2318808A1 CA 002318808 A CA002318808 A CA 002318808A CA 2318808 A CA2318808 A CA 2318808A CA 2318808 A1 CA2318808 A1 CA 2318808A1
- Authority
- CA
- Canada
- Prior art keywords
- membrane
- group
- transplant
- poly
- xylylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title abstract description 13
- 239000007943 implant Substances 0.000 title description 3
- 238000000576 coating method Methods 0.000 claims abstract description 42
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 26
- 125000003118 aryl group Chemical group 0.000 claims abstract description 25
- 239000012528 membrane Substances 0.000 claims description 51
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 26
- 239000011248 coating agent Substances 0.000 claims description 24
- 210000000056 organ Anatomy 0.000 claims description 14
- 102000004877 Insulin Human genes 0.000 claims description 13
- 108090001061 Insulin Proteins 0.000 claims description 13
- 229940125396 insulin Drugs 0.000 claims description 13
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 12
- 235000015097 nutrients Nutrition 0.000 claims description 11
- 238000002054 transplantation Methods 0.000 claims description 10
- -1 poly monochloro-xylylene Polymers 0.000 claims description 9
- 229920000052 poly(p-xylylene) Polymers 0.000 claims description 7
- 229960003638 dopamine Drugs 0.000 claims description 6
- MMIVZWZHLDUCKH-UHFFFAOYSA-N chloromethane;chloromethylbenzene Chemical group ClC.ClCC1=CC=CC=C1 MMIVZWZHLDUCKH-UHFFFAOYSA-N 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 4
- 239000005495 thyroid hormone Substances 0.000 claims description 4
- 229940036555 thyroid hormone Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000004576 sand Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 48
- 230000008073 immune recognition Effects 0.000 abstract description 5
- 241000124008 Mammalia Species 0.000 abstract description 4
- 230000028993 immune response Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 239000000126 substance Substances 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 238000002513 implantation Methods 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 235000010290 biphenyl Nutrition 0.000 description 4
- 239000004305 biphenyl Substances 0.000 description 4
- 238000006664 bond formation reaction Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 150000002790 naphthalenes Chemical class 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011253 protective coating Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 208000005676 Adrenogenital syndrome Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000008448 Congenital adrenal hyperplasia Diseases 0.000 description 2
- 229920004943 Delrin® Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000005859 cell recognition Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 102000034240 fibrous proteins Human genes 0.000 description 2
- 108091005899 fibrous proteins Proteins 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 208000003532 hypothyroidism Diseases 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 229920005597 polymer membrane Polymers 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 238000001771 vacuum deposition Methods 0.000 description 2
- 239000006200 vaporizer Substances 0.000 description 2
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 241000158500 Platanus racemosa Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000010782 T cell mediated cytotoxicity Effects 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 150000001555 benzenes Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 210000003737 chromaffin cell Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000011501 immunologic monitoring Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000002161 passivation Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/013,750 US5922339A (en) | 1998-01-27 | 1998-01-27 | Compositions and methods for biocompatible implants |
| US09/013750 | 1998-01-27 | ||
| PCT/US1999/001051 WO1999037339A2 (en) | 1998-01-27 | 1999-01-19 | Compositions and methods for biocompatible implants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2318808A1 true CA2318808A1 (en) | 1999-07-29 |
Family
ID=21761555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002318808A Abandoned CA2318808A1 (en) | 1998-01-27 | 1999-01-19 | Compositions and methods for biocompatible implants |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US5922339A (enExample) |
| EP (1) | EP1051209B9 (enExample) |
| JP (1) | JP2002500930A (enExample) |
| KR (1) | KR20010040427A (enExample) |
| AT (1) | ATE228864T1 (enExample) |
| AU (1) | AU743253B2 (enExample) |
| CA (1) | CA2318808A1 (enExample) |
| DE (1) | DE69904293T2 (enExample) |
| WO (1) | WO1999037339A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6551618B2 (en) * | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
| DE10047300A1 (de) * | 2000-09-25 | 2002-04-18 | Gustav Steinhoff | Bioartifizielles Verbundmaterial und Verfahren zu seiner Herstellung |
| US7179283B2 (en) * | 2001-11-02 | 2007-02-20 | Scimed Life Systems, Inc. | Vapor deposition process for producing a stent-graft and a stent-graft produced therefrom |
| US20080086792A1 (en) | 2006-10-13 | 2008-04-17 | Thomas Charles Kuracina | Method and apparatus for diverting sweat, liquid, moisture or the like from an eye |
| JP4624678B2 (ja) | 2002-02-21 | 2011-02-02 | パイオニア・サージカル・オーソバイオロジックス，インコーポレイテッド | 架橋生物活性ヒドロゲルマトリックス |
| US8672976B2 (en) | 2007-02-06 | 2014-03-18 | Pioneer Surgical Technology, Inc. | Intervertebral implant devices and methods for insertion thereof |
| US9132021B2 (en) | 2011-10-07 | 2015-09-15 | Pioneer Surgical Technology, Inc. | Intervertebral implant |
| KR20140097256A (ko) | 2011-11-02 | 2014-08-06 | 할사이온, 인크. | 상처 치료를 위한 방법들 및 조성물들 |
| US8940317B2 (en) | 2011-12-23 | 2015-01-27 | Pioneer Surgical Technology | Continuous matrix with osteoconductive particles dispersed therein, method of forming thereof, and method of regenerating bone therewith |
| WO2019051260A1 (en) | 2017-09-08 | 2019-03-14 | Pioneer Surgical Technology, Inc. | IMPLANTS, INSTRUMENTS AND INTERVERTEBRAL METHODS |
| USD907771S1 (en) | 2017-10-09 | 2021-01-12 | Pioneer Surgical Technology, Inc. | Intervertebral implant |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4340458A (en) * | 1980-06-02 | 1982-07-20 | Joslin Diabetes Center, Inc. | Glucose sensor |
| DE3216005C2 (de) * | 1982-04-29 | 1987-02-12 | Serag-Wiessner Catgutfabriken GmbH, 8674 Naila | Verwendung eines vollaromatischen Polyamids mit Phenyleneinheiten und Carbonamidbrücken als Fasermaterial für die chirurgische Wundversorgung, insbesondere für chirurgische Nähzwecke |
| EP0138150A3 (en) * | 1983-10-05 | 1988-06-01 | E.I. Du Pont De Nemours And Company | Diagnostic electrode membranes utilizing specific enzyme/ionophore pairs |
| US4868121A (en) * | 1985-02-07 | 1989-09-19 | Mcdonnell Douglas Corporation | Islet isolation process |
| GB8604497D0 (en) * | 1986-02-24 | 1986-04-03 | Connaught Lab | Separation of islets of langerhans |
| US4756835A (en) * | 1986-08-29 | 1988-07-12 | Advanced Polymer Technology, Inc. | Permeable membranes having high flux-density and low fouling-propensity |
| US4794090A (en) * | 1986-09-26 | 1988-12-27 | W. R. Grace & Co.-Conn. | Immobilization support for biologicals |
| US4788271A (en) * | 1987-03-23 | 1988-11-29 | The United States Of America As Represented By The United States National Aeronautics And Space Administration | Polyphenylquinoxalines containing alkylenedioxy groups |
| US5079160A (en) * | 1987-06-08 | 1992-01-07 | Lacy Paul E | Method to isolate clusters of cell subtypes from organs |
| US5151183A (en) * | 1989-05-18 | 1992-09-29 | Allied-Signal Inc. | Reduction of membrane fouling by surface fluorination |
| FR2669527B1 (fr) * | 1990-11-23 | 1998-12-11 | Asa Laboratoires Prothaid | Orthese de renfort pour le remplacement d'un ligament deficient par un transplant autologue. |
| NL9002764A (nl) * | 1990-12-14 | 1992-07-01 | Tno | Elektrode, voorzien van een polymeerbekleding met een daaraan gebonden redox-enzym. |
| DK0585368T3 (da) * | 1991-04-25 | 1998-03-16 | Univ Brown Res Found | Implanterbart biokompatibelt immunisolatorisk vehikel til afgivelse af udvalgte terapeutiske produkter |
| AU3274693A (en) * | 1991-12-31 | 1993-07-28 | Abbott Laboratories | Composite membrane |
| DE69327281T2 (de) * | 1992-02-24 | 2000-08-10 | Encelle, Inc. | Künstliche endokrine vorrichtung |
| AU5957094A (en) * | 1993-01-15 | 1994-08-15 | Allied-Signal Inc. | Process for producing ion exchange membranes, and the ion exchange membranes produced thereby |
| NZ278809A (en) * | 1994-01-13 | 1998-03-25 | Rogosin Inst | Macroencapsulation of secretory cells in an agarose collagen gel material coated with agarose |
-
1998
- 1998-01-27 US US09/013,750 patent/US5922339A/en not_active Expired - Fee Related
-
1999
- 1999-01-19 WO PCT/US1999/001051 patent/WO1999037339A2/en not_active Ceased
- 1999-01-19 AT AT99902348T patent/ATE228864T1/de not_active IP Right Cessation
- 1999-01-19 JP JP2000528317A patent/JP2002500930A/ja active Pending
- 1999-01-19 DE DE69904293T patent/DE69904293T2/de not_active Expired - Lifetime
- 1999-01-19 EP EP99902348A patent/EP1051209B9/en not_active Expired - Lifetime
- 1999-01-19 CA CA002318808A patent/CA2318808A1/en not_active Abandoned
- 1999-01-19 KR KR1020007008201A patent/KR20010040427A/ko not_active Withdrawn
- 1999-01-19 AU AU22350/99A patent/AU743253B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| DE69904293T2 (de) | 2003-08-14 |
| ATE228864T1 (de) | 2002-12-15 |
| EP1051209B9 (en) | 2003-09-10 |
| WO1999037339A3 (en) | 1999-09-30 |
| AU2235099A (en) | 1999-08-09 |
| JP2002500930A (ja) | 2002-01-15 |
| EP1051209B1 (en) | 2002-12-04 |
| DE69904293D1 (de) | 2003-01-16 |
| WO1999037339A2 (en) | 1999-07-29 |
| KR20010040427A (ko) | 2001-05-15 |
| AU743253B2 (en) | 2002-01-24 |
| US5922339A (en) | 1999-07-13 |
| EP1051209A2 (en) | 2000-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cullen et al. | Developing a tissue-engineered neural-electrical relay using encapsulated neuronal constructs on conducting polymer fibers | |
| CA2354060C (en) | Apparatus and method for control of tissue/implant interactions | |
| Aregueta-Robles et al. | Organic electrode coatings for next-generation neural interfaces | |
| Lu et al. | Mesh-supported submicron parylene-C membranes for culturing retinal pigment epithelial cells | |
| La Flamme et al. | Biocompatibility of nanoporous alumina membranes for immunoisolation | |
| EP1051209B1 (en) | Compositions and methods for biocompatible implants | |
| KR19990067321A (ko) | 전도성 고분자를 이용한 신경자극 방법 및 장치 | |
| Pritchard et al. | The use of surface modified poly (glycerol-co-sebacic acid) in retinal transplantation | |
| US6966322B2 (en) | Enhanced chronic lead removal | |
| Furuzono et al. | Physical and biological evaluations of sintered hydroxyapatite/silicone composite with covalent bonding for a percutaneous implant material | |
| FR2820057A1 (fr) | Membrane pour chambre d'encapsulation de cellules produisant au moins une substance biologiquement active et organe bio-artificiel comprenant une telle membrane | |
| KR100195549B1 (ko) | 생유기체의 생물부, 특히 기관을 생성하기 위한 활성 물질 복합체, 이를 제조하는 방법 및 이의 용도 | |
| Bakker et al. | Biocompatibility of six elastomers in vitro | |
| Han et al. | Hydrogel–electrospun fiber mat composite coatings for neural prostheses | |
| Risbud et al. | Chitosan–polyvinyl pyrrolidone hydrogels as candidate for islet immunoisolation: in vitro biocompatibility evaluation | |
| WO2017180901A1 (en) | Medical device comprising graphene coating | |
| WO2003026489A2 (en) | Biopolymer and biopolymer-cell compositions for nerve tissue repair | |
| JPH07505786A (ja) | 生存可能な細胞の培養法および体液中の化合物濃度の調整法 | |
| WO2006103685A2 (en) | A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue | |
| BERNHARD et al. | Development of a nonthrombogenic collagenous blood-prosthetic interface | |
| JP2022552097A (ja) | 新規な多孔性スキャフォールドおよびその製造方法 | |
| Biagini et al. | Fibroblast proliferation over dialysis membrane: an experimental model for “tissue” biocompatibility evaluation | |
| Yustisia et al. | Effect of Bombyx mori's Sericin Immobilization over Poly (L-Lactic Acid) Surface on Mesenchymal Stem Cells Attachment and Proliferation | |
| Adnot et al. | Staphylococcus epidermidis on orthopaedtc | |
| Botchwey et al. | Christopher D. Pritchard (1), Karin M. Arnér (2), Rebekah A. Neal (3), William L. Neeley (1), Peter Bojo (1), Erika Bachelder (4), Jessica Holz (4), Nicki Watson (4) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |